Bjarnason I, O'Morain C, Levi A J, Peters T J
Gastroenterology. 1983 Aug;85(2):318-22.
Intestinal permeability was assessed in patients with inflammatory bowel disease by measuring the urine excretion of 51chromium-labeled ethylenediaminetetraacetate over periods up to 24 h after oral administration. Twenty-eight control subjects and 10 patients with ulcerative colitis excreted less than 2.6% of the test dose in 24 h. Ten patients with small bowel Crohn's disease excreted 3.3%-14.0%, and 10 of 11 patients with ileocolonic involvement had increased excretion. At the same time, 5 of 11 patients with Crohn's colitis were clearly outside the normal range, suggesting small bowel involvement. The 24-h urine excretion of 51chromium-labeled ethyl-enediaminetetraacetate after oral administration appears to be a sensitive, noninvasive test for assessing small intestinal integrity, and may be a valuable adjuvant in the differential diagnosis of inflammatory bowel disease.
通过在口服给药后长达24小时的时间段内测量51铬标记的乙二胺四乙酸的尿排泄量，对炎症性肠病患者的肠道通透性进行评估。28名对照受试者和10名溃疡性结肠炎患者在24小时内排泄的测试剂量少于2.6%。10名小肠克罗恩病患者排泄量为3.3%-14.0%，11名回结肠受累患者中有10名排泄量增加。同时，11名克罗恩结肠炎患者中有5名明显超出正常范围，提示小肠受累。口服给药后51铬标记的乙二胺四乙酸的24小时尿排泄量似乎是评估小肠完整性的一种敏感、非侵入性测试，并且可能是炎症性肠病鉴别诊断中有价值的辅助手段。
